Lantern Pharma (LTRN) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $0.67, +0.21% vs the prior close of $0.67.
- Volume 257.81K shares, 1.2x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
LTRN ends flat (+0.2%) to $0.67. Closed at $0.67, +0.21% vs the prior close of $0.67. Day range $0.63–$0.73, opened at $0.68.
LTRN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — LTRN ends flat (+0.2%) to $0.67
- Closed at $0.67, +0.21% vs the prior close of $0.67. Day range $0.63–$0.73, opened at $0.68.
- Volume was 257.81K shares, 1.2x its 50-day average of 215.59K.
- Price is -60.4% vs its 50-day average ($1.69) and -74.3% vs its 200-day average ($2.60).
- 52-week range $0.63–$4.58; today's close sits at 1% of that range, 85.4% below the 52-week high.
Oct 15, 2026 — LTRN dips 0.9% to $0.67, a 52-week low, 7 down days in a row
- Closed at $0.67, -0.89% vs the prior close of $0.67. Day range $0.65–$0.71, opened at $0.66.
- Volume was 232.80K shares, 1.1x its 50-day average of 211.99K.
- Price is -61.4% vs its 50-day average ($1.73) and -74.4% vs its 200-day average ($2.61).
- 52-week range $0.65–$4.58; today's close sits at 0% of that range, 85.4% below the 52-week high.
- That makes 7 straight losses.
Oct 14, 2026 — LTRN slides 5.3% to $0.67, a 52-week low, 6 down days in a row
- Closed at $0.67, -5.34% vs the prior close of $0.71. Day range $0.65–$0.71, opened at $0.71.
- Volume was 212.30K shares, 1.0x its 50-day average of 209.40K.
- Price is -62.0% vs its 50-day average ($1.77) and -74.3% vs its 200-day average ($2.62).
- 52-week range $0.65–$4.58; today's close sits at 1% of that range, 85.3% below the 52-week high.
- That makes 6 straight losses.
Oct 13, 2026 — LTRN slides 3.5% to $0.71, a 52-week low, 5 down days in a row
- Closed at $0.71, -3.53% vs the prior close of $0.74. Day range $0.70–$0.80, opened at $0.72.
- Volume was 162.50K shares, 0.8x its 50-day average of 208.45K.
- Price is -60.8% vs its 50-day average ($1.81) and -73.0% vs its 200-day average ($2.64).
- 52-week range $0.70–$4.58; today's close sits at 0% of that range, 84.5% below the 52-week high.
- That makes 5 straight losses.
Oct 12, 2026 — LTRN slides 9.3% to $0.74, a 52-week low, 4 down days in a row
- Closed at $0.74, -9.35% vs the prior close of $0.81. Day range $0.72–$0.85, opened at $0.85.
- Volume was 184.00K shares, 0.9x its 50-day average of 205.73K.
- Price is -60.2% vs its 50-day average ($1.85) and -72.2% vs its 200-day average ($2.65).
- 52-week range $0.72–$4.68; today's close sits at 0% of that range, 84.3% below the 52-week high.
- That makes 4 straight losses.
Oct 9, 2026 — LTRN dips 2.0% to $0.81, a 52-week low, 3 down days in a row
- Closed at $0.81, -2.05% vs the prior close of $0.83. Day range $0.76–$0.83, opened at $0.83.
- Volume was 274.90K shares, 1.4x its 50-day average of 201.78K.
- Price is -57.0% vs its 50-day average ($1.89) and -69.5% vs its 200-day average ($2.66).
- 52-week range $0.76–$4.69; today's close sits at 1% of that range, 82.7% below the 52-week high.
- That makes 3 straight losses.
Oct 8, 2026 — LTRN slides 8.8% to $0.83, a 52-week low
- Closed at $0.83, -8.79% vs the prior close of $0.91. Day range $0.83–$0.90, opened at $0.89.
- Volume was 250.30K shares, 1.3x its 50-day average of 197.50K.
- Price is -56.9% vs its 50-day average ($1.93) and -69.0% vs its 200-day average ($2.68).
- 52-week range $0.83–$4.70; today's close sits at 0% of that range, 82.4% below the 52-week high.
Oct 7, 2026 — LTRN slides 4.6% to $0.91
- Closed at $0.91, -4.61% vs the prior close of $0.95. Day range $0.89–$1.00, opened at $0.95.
- Volume was 223.50K shares, 1.2x its 50-day average of 194.34K.
- Price is -53.6% vs its 50-day average ($1.96) and -66.2% vs its 200-day average ($2.69).
- 52-week range $0.84–$4.70; today's close sits at 2% of that range, 80.7% below the 52-week high.
Oct 6, 2026 — LTRN rises 1.5% to $0.95 on 2.1x normal volume
- Closed at $0.95, +1.49% vs the prior close of $0.94. Day range $0.92–$1.07, opened at $0.96.
- Volume was 388.60K shares, 2.1x its 50-day average of 187.33K — unusually heavy trading.
- Price is -52.2% vs its 50-day average ($1.99) and -64.7% vs its 200-day average ($2.70).
- 52-week range $0.84–$4.70; today's close sits at 3% of that range, 79.7% below the 52-week high.
Oct 5, 2026 — LTRN jumps 9.3% to $0.94
- Closed at $0.94, +9.30% vs the prior close of $0.86. Day range $0.86–$0.97, opened at $0.88.
- Volume was 276.10K shares, 1.5x its 50-day average of 183.08K.
- Price is -53.7% vs its 50-day average ($2.03) and -65.3% vs its 200-day average ($2.71).
- 52-week range $0.84–$4.70; today's close sits at 3% of that range, 80.0% below the 52-week high.
Oct 2, 2026 — LTRN slides 14.0% to $0.86, a 52-week low on 2.5x normal volume
- Closed at $0.86, -14.00% vs the prior close of $1.00. Day range $0.84–$1.04, opened at $1.03.
- Volume was 432.30K shares, 2.5x its 50-day average of 176.15K — unusually heavy trading.
- Price is -58.4% vs its 50-day average ($2.07) and -68.4% vs its 200-day average ($2.72).
- 52-week range $0.84–$4.70; today's close sits at 1% of that range, 81.7% below the 52-week high.
- That makes 5 straight losses.
LTRN latest news & SEC filings
Every SEC filing by or about LTRN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 8, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Oct 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.01 — Stock exchange listing notice or transfer of listing.
Sep 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
Sep 30, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 14, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$7.07M (prior year -$4.33M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.57 (prior year -$0.40) (loss widened vs Jun 30, 2025)
Aug 4, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 23, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade LTRN
- Last results release: Aug 14, 2026 (8-K Item 2.02). Previous ones: May 15, 2026, Mar 30, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 13, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 5.36% (largest 14.0%). That is a volatile stock.
- Liquidity: about 320.75K shares (≈$214.39K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.67 vs a range of $0.63–$4.58 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 8 open-market buys, 0 sales; latest: Lee Troy Schalop bought 48,544 shares on May 12, 2026.
- Latest filings: 8-K Oct 1, 2026; 8-K Sep 30, 2026; 8-K Sep 24, 2026.
- Share count: 12.78M shares outstanding (Aug 10, 2026), +18.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
LTRN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 0.68 | 0.73 | 0.63 | 0.67 | 257.81K |
| Oct 15, 2026 | 0.66 | 0.71 | 0.65 | 0.67 | 232.80K |
| Oct 14, 2026 | 0.71 | 0.71 | 0.65 | 0.67 | 212.30K |
| Oct 13, 2026 | 0.72 | 0.80 | 0.70 | 0.71 | 162.50K |
| Oct 12, 2026 | 0.85 | 0.85 | 0.72 | 0.74 | 184.00K |
| Oct 9, 2026 | 0.83 | 0.83 | 0.76 | 0.81 | 274.90K |
| Oct 8, 2026 | 0.89 | 0.90 | 0.83 | 0.83 | 250.30K |
| Oct 7, 2026 | 0.95 | 1.00 | 0.89 | 0.91 | 223.50K |
| Oct 6, 2026 | 0.96 | 1.07 | 0.92 | 0.95 | 388.60K |
| Oct 5, 2026 | 0.88 | 0.97 | 0.86 | 0.94 | 276.10K |
| Oct 2, 2026 | 1.03 | 1.04 | 0.84 | 0.86 | 432.30K |
| Oct 1, 2026 | 1.00 | 1.05 | 0.98 | 1.00 | 253.60K |
| Sep 30, 2026 | 1.10 | 1.16 | 0.97 | 1.01 | 420.60K |
| Sep 29, 2026 | 1.11 | 1.12 | 1.01 | 1.09 | 363.70K |
| Sep 28, 2026 | 1.25 | 1.27 | 1.08 | 1.09 | 461.40K |
| Sep 25, 2026 | 1.19 | 1.28 | 1.16 | 1.22 | 219.80K |
| Sep 24, 2026 | 1.36 | 1.36 | 1.16 | 1.21 | 514.90K |
| Sep 23, 2026 | 1.35 | 1.54 | 1.34 | 1.39 | 292.20K |
| Sep 22, 2026 | 1.45 | 1.64 | 1.35 | 1.36 | 747.00K |
| Sep 21, 2026 | 1.59 | 1.62 | 1.47 | 1.50 | 246.60K |
About Lantern Pharma
Lantern Pharma (LTRN) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in DALLAS, TX. State of incorporation: TX. Fiscal year ends December 31. SEC CIK 1763950.
LTRN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Vijay Chandru | Director | Jan 13, 2026 |
| D Jeffrey Keyser | Director | May 14, 2026 |
| Maria-Luisa Maccecchini | Director | Jan 13, 2026 |
| Lee Troy Schalop | Director | May 14, 2026 |
| David S. Silberstein | Director | Jan 13, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Kishor G. Bhatia | Chief Scientific Officer | Dec 22, 2025 |
| David R. Margrave | Chief Financial Officer | Dec 22, 2025 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 12, 2026 | Lee Troy Schalop | Buy | 48,544 | $2.06 |
| May 12, 2026 | Lee Troy Schalop | Buy | 48,544 | $2.06 |
| May 12, 2026 | Lee Troy Schalop | Buy | 48,544 | $2.06 |
| May 12, 2026 | Lee Troy Schalop | Buy | 48,544 | $2.06 |
| May 12, 2026 | D Jeffrey Keyser | Buy | 48,544 | $2.06 |
| May 12, 2026 | D Jeffrey Keyser | Buy | 48,544 | $2.06 |
| May 12, 2026 | D Jeffrey Keyser | Buy | 48,544 | $2.06 |
| May 12, 2026 | D Jeffrey Keyser | Buy | 48,544 | $2.06 |
LTRN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-17.12M | -1.57 | $-15.68M |
| Dec 31, 2024 | — | $-20.78M | -1.93 | $-17.81M |
| Dec 31, 2023 | — | $-15.96M | -1.47 | $-14.35M |
| Dec 31, 2022 | — | $-14.26M | -1.31 | $-12.77M |
| Dec 31, 2021 | — | $-12.36M | — | $-10.59M |
Latest balance sheet: total assets $8.60M, total liabilities $11.82M, cash $6.66M (as of Jun 30, 2026).
LTRN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 14, 2026 | 8-K Item 2.02 (results) | $2.65 |
| May 15, 2026 | 8-K Item 2.02 (results) | $3.14 |
| Mar 30, 2026 | 8-K Item 2.02 (results) | $1.24 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $3.46 |
| Aug 13, 2025 | 8-K Item 2.02 (results) | $4.76 |
| May 15, 2025 | 8-K Item 2.02 (results) | $3.86 |
| Mar 27, 2025 | 8-K Item 2.02 (results) | $3.72 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $3.42 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 18, 2024 | 8-K Item 2.02 (results) | — |
| Nov 8, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on LTRN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.